Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Vitamin E status in subjects with MetS
- What is the metabolic syndrome (MetS)?
- Adverse consequences of MetS
- Vitamin E: why do we need it?
- Lipid peroxidation chain reaction
- Vitamin E: chain-breaking antioxidant
- Linkage of antioxidant defense mechanisms
- Implications for human health
- Catabolism of chylomicrons by lipoprotein lipase
- Vitamin E delivery during chylomicron catabolism
- Preferential secretion of α–tocopherol in VLDL
- Vitamin E absorption increases with fat intake
- α–Tocopherol bioavailability in adults with MetS
- Objective: α–Tocopherol bioavailability in MetS
- Design: α–tocopherol bioavailability in MetS
- Participant characteristics at baseline
- Characteristics baseline antioxidants & cytokines
- Sample collection overview
- No effect of fat on α–tocopherol
- MetS subjects have 20% lower AUCs
- No effect of fat on α–tocopherol Cmax, Tmax
- MetS have slower α–tocopherol elimination rate
- MetS have lower Cmax, AUC and absorption
- Lower Cmax, AUC & absorption confirmed
- Summary (1)
- ⍺-CEHC as a biomarker of vitamin E in MetS
- a-Tocopherol measurement & vit E supplements
- Regulation of liver vitamin E
- α-Tocopherol and its metabolite
- The UCLA energetics study
- Dietary assessment: 24- hour recall
- Self-reported dietary intakes
- Major contributors to dietary vitamin E intakes
- α-CEHC as a predictor of α-tocopherol adequacy
- Dietary α-tocopherol and α-CEHC (1)
- Dietary α-tocopherol and α-CEHC (2)
- Urinary α-CEHC cutoff point
- Vitamin E metabolites as a marker of its status
- α-CEHC shows lower vitamin E status in MetS
- Lower excretion of d6α-CEHC &CMBHC in MetS
- d6α-CEHC concentrations in Healthy & MetS
- Lower plasma d6α-CEHC concentrations in MetS
- Urinary & Plasma d6-α-CEHC are highly correlated
- Correlation of Urinary & Plasma d6-α-CEHC AUCs
- Summary (2)
- Hypothetical scheme of α-tocopherol trafficking
- Conclusion
- Acknowledgements
- Linus Pauling institute
Topics Covered
- Introduction to the role of vitamin E as an antioxidant
- Importance of vitamin E in human health
- Mechanisms of absorption and lipoprotein transport
- Introduction to the Metabolic Syndrome
- Pharmacokinetics of Vitamin E in healthy adults and those with metabolic syndrome
- Role of fat in vitamin E absorption
- Catabolism of vitamin E
- Introduction to a biomarker of vitamin E status; alpha-CEHC
- Demonstration of alpha-CEHC as a biomarker of bioavailability
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Traber, M. (2019, February 28). Vitamin E and the metabolic syndrome [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/EFRY5008.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Maret Traber has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Metabolism & Nutrition
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Maret Traber.
I'm at the Linus Pauling Institute at Oregon State University in Corvallis, Oregon
in the United States.
Today I'd like to talk to you about our studies
concerning vitamin E and persons with metabolic syndrome.
0:22
I'd like to cover the topics of what is metabolic syndrome,
then briefly review what is known about vitamin E absorption and transport,
cover interesting new studies concerning
vitamin E pharmacokinetics in metabolic syndrome subjects,
and then, finally, tell you about a new vitamin E biomarker Alpha-CEHC.
We'll cover results from two different trials;
one is a UCLA diet study and the other is the results from
the pharmacokinetic study that was done in metabolic syndrome subjects at Ohio State University.
1:11
So, what is the metabolic syndrome?
In general, these are a series of abnormalities including elevated blood pressure,
high blood sugar, excess visceral body fat,
elevated circulating triglycerides, and low HDL cholesterol.
This diagnosis is made clinically when a person has three out of five
of these components including waist circumference that is too large,
elevated blood pressure, elevated triglycerides,
low HDL cholesterol, and elevated plasma glucose.
Note that the elevations can still be within
the normal range, but it is the combination that is concernful.